A randomised phase II trial comparing docetaxel plus prednisone with docetaxel plus prednisone plus low-dose cyclophosphamide in castration-resistant prostate cancer

Chemotherapy

Volumn 60, Issue 2, 2014, Pages 129-134

  Porsch, Markus ^a   Ulrich, Matthias ^b   Wendler, Johann Jakob ^a   Liehr, Uwe Bernd ^a   Reiher, Frank ^c   Janitzky, Andreas ^a   Baumunk, Daniel ^a   Schindele, Daniel ^a   Seseke, Florian ^d   Lux, Anke ^a   Schostak, Martin ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b AMEOS Klinikum St Salvator   (Germany)

^c AMEOS Klinikum Haldensleben   (Germany)

^d Krankenhaus Martha Maria   (Germany)

Author keywords

Castration resistant prostate cancer; Cyclophosphamide; Docetaxel; Prednisone; Prostate cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

ARTICLE; BONE PAIN; BRONCHOPNEUMONIA; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EVENING DOSAGE; EXTRAVASATION; FATIGUE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; HUMANS; MALE; MIDDLE AGED; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT OUTCOME;

EID: 84925382750     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000369781     Document Type: Article

References (26)

1. Gesundheitsberichterstattung des Bundes, Zentrum für Krebsregisterdaten: Krebs in Deutschland 2009/2010, ed 9. Berlin, Robert Koch-Institut, 2013, p 16
2. Gesundheitsberichterstattung des Bundes, Zentrum für Krebsregisterdaten: Krebs in Deutschland 2009/2010, ed 9. Berlin, Robert Koch-Institut, 2013, p 17
3. Gesundheitsberichterstattung des Bundes, Zentrum für Krebsregisterdaten: Krebs in Deutschland 2009/2010, ed 9. Berlin, Robert Koch-Institut, 2013, p 89
4. Eisenberger MA, Abrams JS: Chemotherapy for prostatic carcinoma. Semin Urol 1988; 6: 303-310
5. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098-1111
6. Perry CA, McTravish D: Estramustine phosphate sodium: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995; 7: 149-174
7. Picus J, Schultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormonerefractory prostate cancer: preliminary results. Semin Oncol 1999; 26(suppl 17):14-18
8. Friedland D, Cohen J, Miller R Jr, Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt P: A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999; 26(suppl 17):19-23
9. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD: Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 123-128
10. Berry W, Dakhil S, Gregurich MA, Asmar L: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001; 28(suppl 15):8-15
11. Gravis G, Bladou F, Salem N, Macquart-Moulin G, Serment G, Camerlo J, Genre D, Bardou VJ, Maraninchi D, Viens P: Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 2003; 98: 1627-1634
12. Schutz FA, Buzaid AC, Sartor O: Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity. Crit Rev Oncol Hematol 2014; 91: 248-256
13. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512
14. Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson M, Small EJ, Raghaven D, Crawford ED: Docetaxel and Estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520
15. Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard J-C, Logothetis CJ, Pignon J-P, Michiels S: Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a metaanalysis of individual patient data. Lancet Oncol 2007; 8: 994-1000
16. Engels FK, Sparreboom A, Mathot RAA, Verweij J: Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 2005; 93: 173-177
17. Raghavan D, Cox K, Pearson BS, Coorey GJ, Rogers J, Watt WH, Coates AS, McNeil E, Grygiel JJ: Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol 1993; 72: 625-628
18. Daliani DD, Assikis V, Tu SM, Papandreou CN, Pagliaro LC, Holtkamp T, Wang X, Thall PF, Logothetis CJ: Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 2003; 97: 561-567
19. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R: Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003; 98: 1643-1648
20. Diaz JF, Andreu JM: Assembly of purified GDP-tubulin into microtubules induced by taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747-2755
21. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV: Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005; 11: 6678-6685
22. Nelius T, Klatte T, Reiher F, Filleur S, Yap R, Allhoff EP: Randomized study of docetaxel and dexamethasone with low or high dose estramustine for patients with advanced hormone-refractory prostate cancer (astract 4653). Proc Am Soc Clin Oncol 2006; 24: 254s
23. Nakagawa M, Terashima T, D'yachkova Y, Bondy GP, Hogg JC, van Eeden SF: Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 1998; 98: 2307-2313
24. Cyclophosphamide: Fachinformation. Weiterstadt, Baxter Oncology, 2014
25. Leo S, Accettura C, Lorusso V: Castration-resistant prostate cancer: targeted therapies. Chemotherapy 2011; 57: 115-127
26. Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ: Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol 2013; 25: 406-430.